• About
  • Subscribe
  • Advertise
  • Contact
Thursday, December 5, 2024
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Eye disease

Latest bionic eye trial demonstrates long-term durability

by Staff Writer
June 19, 2024
in Eye disease, Inherited retinal disease, Local, News, Research, Retinitis pigmentosa
Reading Time: 3 mins read
A A
New findings demonstrate the device stayed in place behind the retina without complication, with 97% of electrodes functioning 2.7 years after first implant. dragonstock/adobe.stock.com

New findings demonstrate the device stayed in place behind the retina without complication, with 97% of electrodes functioning 2.7 years after first implant. dragonstock/adobe.stock.com

Share on FacebookShare on Twitter

Outcomes from the bionic eye trial have demonstrated the device’s long-term durability and stability in the retina.

The detailed outcomes from the trial led by the Centre for Eye Research Australia (CERA), Bionics Institute, University of Melbourne and Royal Victorian Eye and Ear Hospital, are published in Ophthalmology Science.

The findings add to interim results which showed that the second-generation bionic eye developed by Australian company Bionic Vision Technologies provided rapid improvements for four patients with blindness caused by retinitis pigmentosa.

The bionic eye comprises an electrode array, designed by the Bionics Institute and CERA, that is surgically implanted behind the eye. The electrode receives signals from a video camera mounted on glasses, which stimulate the patient’s retina.

Professor James Fallon, head of research at the Bionics Institute said: “The camera converts images into electrical pulses delivered by the electrode array that activate retinal cells and create flashes of light called phosphenes to help patients detect edges, shapes and movement.”

The new study tracked the patients from the time they received the implant surgery in 2018 to 2021. Its findings demonstrate the device stayed in place behind the retina without complication, with 97% of electrodes functioning 2.7 years after first implant.

Principal Investigator and vitreoretinal surgeon Associate Professor Penny Allen said patients showed significant improvement in their navigation, mobility and ability to detect objects – in clinical tests, at home and in the community.

“The bionic eye enabled blind patients to locate doorways, avoid obstacles and find items on table-tops,” she said.

“They reported greater confidence in navigation, were more likely to explore new environments and had reduced need for assistance when travelling to the local shops.”

A/Prof Allen said participants reported that the bionic eye supplemented long cane and guide dog use, provided safe navigation around people and obstacles, and allowed them to detect waypoints such as trees and lamp posts along navigational routes.

“Patients were also able to locate their spouse in a café and detect people moving at a train station – things they could not do without using their bionic eye.”

Bionic Vision Technologies’ team is continuing to refine the vision processing capabilities, usability, as well as the wearables of the bionic eye system.

Dr Ash Attia, CEO of Bionic Vision Technologies said: “We are encouraged by the excellent results of the generation two bionic eye trial. We are looking forward to finalising the development of the generation three bionic eye and enter the worldwide pivotal trial and ultimately gain regulatory approval.

“Regulatory approval will allow us to make this important technology available to retinitis pigmentosa patients which will positively impact their lives.”

More reading 

Australians at the cutting-edge of gene therapy research

Cerulea Clinical Trials to boost access to sight-saving therapies

Related Posts

Or lack of it, depending on where you live, is the concern of the CPMC and others. Image: BJP7images/stock.adobe.com.

Health ministers warned that fast-track changes could bring ‘postcode’ health care

by Staff Writer
December 5, 2024

Australia’s state health ministers have been warned that the proposed fast-track registration of Specialist International Medical Graduates (SIMGs) risks exacerbating...

Alcon has confirmed its new Unity systems are now registered in Australia, and will be commercially available in 2025. Image: Konektus Photo/Shutterstock.com.

All-new Alcon Unity vitreoretinal and cataract systems approved in Australia

by Myles Hume
December 4, 2024

Alcon has revealed its “highly anticipated” Unity Vitreoretinal Cataract System and Unity Cataract System have been included on the Australian...

Theo Charalambous (left) is the new president of Optometry Australia. Also getting new roles on the board are Shavu Bose, Ramy Aziz and Elise Pocknee-Clem. Image: Optometry Australia.

Changes at the top in Optometry Australia national board shuffle

by Staff Writer
December 3, 2024

Mr Theo Charalambous has been appointed president and Mr Shuva Bose as vice-president of Optometry Australia (OA). Charalambous succeeds Ms...

Join our newsletter

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited